tions are well studied, it is easy to factor the impact events with increased iron storage [26, 27] , while others demonstrate no relationship [28] [29] [30] . A recent review into risk-reward considerations. Two intravenous agents used in Europe, iron saccharate and ferric summarized the existing literature, with a conclusion that 'iron overload states do not appear to be strongly gluconate, are likely to cause less anaphylactoid reactions. There is little published data to help quantitate associated with increased risk of atherosclerotic disease' [31] . Nonetheless, because of the great burden of the risk with these drugs.
As intravenous iron use has increased in haemo-cardiovascular disease in end-stage renal disease, further study in this area is warranted. dialysis patients, questions have been raised as to the safety of ongoing exposure to these agents.
The risk of infection in patients treated with intravenous iron has been of some interest. Iron is an Particularly, there has been concern about iron's oxidative properties, the risk for infection or cardiovascular important growth factor for microorganisms, and as such it is biologically plausible that iron could increase disease, and the possibility of iron overload itself.
Iron is a reactive substance, with oxidative properties infection risk. In the laboratory, it has been shown that excess free iron can enhance the infectivity of that are highly valuable to the body in the production of energy. Living organisms devote much effort to certain bacteria [32] . In animal studies, excess iron has been demonstrated to convert mild into severe infecsequestering iron so that the oxidative nature of free iron does not damage normal tissues. As such, the tions [33] . In humans, the role that iron might play in the risk for infections is not known. The genetic human body typically contains approximately 4000 mg of iron, yet concentrations of free iron that are so low disease, haemochromatosis, causes profound long-term exposure to severe iron overload, and as such it is a as to be nearly unmeasurable [20] . With certain diseases that cause severe overload of iron, such as reasonable first place to look for such a relationship.
It is not clear that these patients have any increase in haemochromatosis, iron can no longer be safely sequestered, and tissue damage may result from free iron risk for infection, although certain highly iron-sensitive bacteria, such as Y. enterocolitica, do cause clinically exposure. In haemochromatosis, oxidative injury to the heart, liver, pancreas and other organs may cause relevant infections in these patients [34] . In addition, after treatment with desferrioxamine (DFO), haemoprofound morbidity [21] . This occurs over decades of organ exposure to very high ambient iron levels. There chromatosis patients have rarely developed infections probably due to increased iron exposure (dialysis is nothing about end-stage renal disease itself that predisposes to iron accumulation [in fact, haemodia-patients have also occasionally been infected during DFO therapy) [35] . lysis leads to ongoing negative iron balance]. It is possible, however, that with long-term indiscriminate While iron seems to be a growth factor for microorganisms, iron excess may also predispose to infection use of intravenous iron that iron overload might occur. In this case oxidative damage to tissue and organs due by hindering host defenses. A recent study reported by Patruta et al. found that bacterial killing in haemodiato free iron could result. Measures such as the serum ferritin are not very accurate for the detection of iron lysis patients is diminished when the serum ferritin was greater than 650 ng/ml (although the transferrin satoverload [22] . As such, relatively low levels must be chosen to avoid the risk of excess iron accumulation. uration was <20%). In addition, neutrophils from a group of patients with iron overload due to haematolIn the US, the NKF-DOQI panel chose a serum ferritin of 800 ng/ml as an upper limit to intravenous iron ogic disease also exhibited altered phagocytic function.
Taken together these results suggest that excess iron treatment [6 ] . This level should effectively rule out the possibility of iron overload and the risk of oxidative may indeed tend to inhibit an important component of host defense. It is difficult, however, to translate tissue damage.
Other than via chronic iron overload, another hypo-this laboratory finding into an understanding of potential clinical impact. The authors simply recommended thetical means of oxidative tissue injury could occur as endothelial damage due to free iron release from avoiding overtreatment with intravenous iron [36 ] .
As we move from laboratory studies of iron and intravenous iron compounds. Generally these agents bind iron quite tightly, with iron dextran having a infection risk to trying to understand the implications for patients, we may begin by considering anecdotal remarkably high dissociation constant. Other agents such as ferric gluconate and iron saccharate bind iron clinical experience. The genetic disease haemochromatosis, as mentioned above, does not appear to with less avidity [23] , yet there is little evidence to suggest that clinically significant free iron release occurs be associated with a noticeably increased risk of infection. Another disease state in which iron overload was with these, or any intravenous iron products.
The issue of increased risk of cardiovascular disease common was end-stage renal disease, prior to the introduction of rHuEpo. Anecdotally, it does not with the use of intravenous iron is of interest. The plausibility of this relationship hinges on the fact that appear that infection risk was greater in that time period, although good data is not available. These free iron, via the Haber-Weiss reaction, can induce the production of reactive oxygen species [24] . The clinical observations are helpful, and serve as prima facie evidence that suggests that iron overload probably resulting lipid peroxidation might accelerate systemic atherosclerotic disease [25] . The clinical significance of does not increase infection risk to any great degree.
To critically establish such a relationship, a randomized this is unclear. Population studies have yielded mixed results, some demonstrating increased risk for cardiac clinical trial would be needed. There would be several ways to design such a study to provide a 'pure' answer second study controlled better for covariates, and found substantially less risk. to the question. To the best of my knowledge, no such studies have been reported in the English-language
The current state of the literature relating to iron and infection risk in dialysis patients does not allow literature. Those studies that have been published suffer from suboptimal methodologies that make it difficult for firm conclusions as to whether iron plays a role in infection risk. In developing risk-reward considerato link cause and effect. Most studies in dialysis patients were performed prior to the introduction of rHuEpo, tions, it is difficult to factor this issue in a meaningful way. The following statements may summarize our when transfusion of blood was the primary treatment for anaemia. This confounds analyses, in that blood current understanding of this issue: (i) it is biologically plausible that iron may play a role in infection, (ii) a transfusion causes iron loading, but also causes immunosuppression which directly impacts the risk for rigorous quantification of risk in dialysis patients is not possible at the present time, (iii) the 1998 Hoen infection. In addition, the use of serum ferritin as the marker of iron load is problematic in that infection study makes clear that factors other than iron are the primary predictors of infection risk in dialysis patients. itself raises the serum ferritin independent of iron status.
The role of iron, if any, would therefore be minimal in comparison. Tielmanns et al. in a retrospective review, found that when the serum ferritin was >500 ng/ml in haemodia-
The risks of iron therapy, both known and hypothetical must be weighed against the well-recognized benelysis patients the risk for infection was increased by approximately five-fold [37] . Seifert et al. found pro-fits of therapy. Intravenous iron is highly efficacious for improving the response of haemodialysis patients gressively higher rates of bacterial infections at serum ferritin levels >330 ng/ml [38] . Similarly, Hoen et al. to rHuEPO. This is supported by a broad literature of clinical studies [9] [10] [11] [12] [13] [14] [15] [16] [17] . The use of intravenous iron is found risk for bacteraemia to be increased when the serum ferritin was >500 ng/ml [39] . The Hoen study vital to allow haemodialysis patients to reach the NKF-DOQI target haematocrit of 33-36%. The panel stated, was performed in an era when rHuEpo use was not commonplace. Given the profound effect of rHuEpo in guideline 8, 'To achieve and maintain a hematocrit of 33-36%, most haemodialysis patients will require treatment on iron status, the investigators performed a similar study that was reported in 1998. This pro-intravenous iron on a regular basis' [6 ] . Since haematocrit levels below 33% have been associated with an spective study included 988 haemodialysis patients from 19 French haemodialysis centres. Four independ-increased risk of hospitalization and death, intravenous iron is clearly a necessity to improve patient outcomes. ent risks for bacteraemia were identified by multivariate analysis: (i) catheter as vascular access, (ii) a prior
In conclusion, it is not likely that intravenous iron treatment exposes the dialysis patient to material risk. history of bacteraemia, (iii) use of immunosupressive therapy, and (iv) lower haemoglobin concentration. Much of our understanding about the risk of iron treatment, however, is incomplete. Given current Regarding iron, neither the serum ferritin concentration nor treatment with iron itself were related to risk knowledge, the NKF-DOQI recommendation not to exceed a serum ferritin of 800 ng/ml should greatly for infection [40] . This study is probably the best study to date of this subject, in that it was prospective, reduce the risk of therapy. Because of the importance of iron management to optimal anaemia therapy, intramulticentre, and rich in clinical data.
In contrast to the Hoen study, studies presented at venous iron treatment remains a standard of care for many patients on haemodialysis. the 1997 and 1998 ASN conference by Collins' group found a positive association between intravenous iron dextran treatment and risk of infection. These were claims-based analyses from Medicare data. In the 1997 References analysis of 33 120 haemodialysis patients, a 35% 
